Feed BTAI
BT

BioXcel Therapeutics, Inc.

BTAI · NASDAQ

$0.07 -18.79% (-$0.02)
1M -90.28%
Market Cap $2.28M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9
Valuation
57 /100
Fair
P/S 3.08x
PEG N/A
P/B N/A
Growth
100 /100
Growing
Rev. growth 19.63%
FCF growth N/A
Book val. growth N/A
Profitability
18 /100
Weak
Net margin 9,549.86%
Op. margin 6,014.42%
FCF margin 6,860.38%
Quality
58 /100
Average
ROA 246.05%
Asset turnover 0.03x
ROIC 1,144.58%
Debt
0 /100
High
Int. coverage -3.11x
Current ratio 0.21x
Net debt/EBITDA N/A
Stability
19 /100
Unstable
Rev. volatility 170.96%
EPS volatility 46.04%
Profitable years 0

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre BTAI
Online

Despre companie

BioXcel Therapeutics, Inc. (BTAI) is a biotechnology company that focuses on researching and developing new therapeutic approaches using artificial intelligence and data analysis. The company leverages advanced technologies and algorithms to identify and develop drugs for various diseases, including neurological and psychiatric disorders. With an innovative approach to drug development and treatment using artificial intelligence, the shares of BioXcel Therapeutics, Inc. (BTAI) may represent an intriguing investment opportunity for investors interested in biotechnology and medical research.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Vimal D. Mehta

Employees

29

Headquarters

New Haven

Evenimente viitoare

11 NOV.

Earnings

Upcoming earnings report

50d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.